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ardiac Magnetic Resonance
maging Identification of
yocardial Fibrosis
he Need for
tandardization and Therapies*
hristopher M. Kramer, MD
harlottesville, Virginia
nvestigators in the 1980s observed increased signal in
nfarcted myocardium after infusion of gadolinium-chelate
n animal models using cardiac magnetic resonance (CMR)
1), but the pulse sequence used was suboptimal for clinical
pplication. With the improved pulse sequence developed
y Simonetti et al. (2), imaging of scar associated with
yocardial infarction (MI) (3) and identification of its
ransmurality was shown to be clinically relevant (4). Soon
hereafter, it was recognized that late gadolinium enhance-
ent (LGE), also called delayed-enhanced CMR, was not
pecific for infarction but was a marker of myocardial
brosis of any etiology. In the past decade, the use of LGE
as rapidly expanded for imaging of myocardial fibrosis in a
yriad of cardiac conditions, including dilated cardiomyop-
thy (5), hypertensive and hypertrophic cardiomyopathy
HCM) (6), infiltrative cardiomyopathies (7,8), and end-
tage renal disease (9) (before the recognition of the asso-
iation of nephrogenic systemic fibrosis and gadolinium
helates).
See page 278
The presence of LGE is a marker of adverse cardiac
utcome in coronary artery disease. Kwong et al. (10)
emonstrated in patients presenting for evaluation for isch-
mic heart disease that the presence of any LGE was a
arker of an increased risk of major adverse cardiac events
MACE). The same was true in diabetic patients without a
nown history of CAD (11). In patients referred to the
atheterization laboratory, the presence of previously unrec-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ramer is supported in part by R01 HL075792, and receives research equipment
upport from Siemens Medical Solutions.gnized MI as identified by LGE is also associated with a
arkedly worse prognosis (12). The presence of a gray zone
f intermediate signal at the border zone of MI has also
een associated with adverse prognosis, thought to be due to
n increased risk of ventricular arrhythmias originating in
his region of admixture of infarcted and normal myocar-
ium (13–15).
The adverse prognosis associated with LGE has now
een extended to a diverse array of cardiomyopathies. In
ilated nonischemic cardiomyopathy, the presence of a
idwall stripe of LGE is associated with inducibility of
entricular arrhythmias (16) and a worse cardiac prognosis,
specially ventricular arrhythmias and hospital stay for
ongestive heart failure (17). In HCM, the presence of
GE is associated with increased risk of ventricular arrhyth-
ias (18), and there are emerging data that it is associated
ith an increased risk of death and other adverse cardiac
vents.
In this issue of the Journal, Azevedo et al. (19) present the
esults of a study of 54 patients scheduled for aortic valve
eplacement (AVR) for either aortic stenosis or regurgita-
ion. They performed LGE in standard fashion, and mac-
oscopic fibrosis was noted in 65% of the patients. However,
hey went beyond standard qualitative analysis and examined
he images quantitatively by measuring the increased signal
ithin the myocardium over a certain threshold based on an
lgorithm defined by their laboratory. They found that quan-
itatively 3.7% of the myocardium demonstrated increased
ignal intensity, and this correlated well with quantitative
nalysis of fibrosis by histopathology from the septal biop-
ies of these patients during AVR. The amount of fibrosis
as a multivariate predictor of all-cause mortality and, in a
ubset of these patients, predicted lack of improvement of
jection fraction after AVR. Another recent study has
hown that the absence of fibrosis was associated with good
rognosis after AVR for AS and that the extent of LGE did
ot change after AVR (20). These are important reports
hat demonstrate the clinical significance of myocardial
brosis in aortic valve disease.
However, a problem in the field is the lack of standard-
zation of methodologies to measure increased myocardial
ignal after gadolinium administration. There are 3 pub-
ished studies, each with their own methodology to measure
he size of the gray border zone after MI (13–15). The
resent study presents yet another technique for quantifica-
ion of increased signal. The field could be improved by the
nstitution of T1-mapping, a technique introduced clinically
n patients with congestive heart failure by Iles et al. (21).
hese authors presented a novel T1-mapping method to
emonstrate the diffuse increase in signal associated with
yocardial fibrosis, which in many conditions might not be
dentified as focal LGE. In a small subset of 9 patients who
nderwent biopsy, the signal intensity measured by CMR
orrelated with the presence of fibrosis. Because fibrosis is
ore commonly microscopic in many of these conditions,
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July 20, 2010:288–9 CMR and Myocardial Fibrosis in Aortic Valve Diseasehe application of a method to measure it such as T1-
apping would be a major advance in the field.
The present study extends the list of cardiac conditions
or which the presence of fibrosis is associated with adverse
utcome. Now that these associations have been defined,
he next step is to identify therapies based upon these
ndings that might alter outcomes. For example, in HCM,
t might be that the presence and/or extent of LGE might
efine the need for an implantable cardioverter-defibrillator.
n valvular heart disease or hypertensive heart disease, the
resence and/or extent of fibrosis might be an indication for
articular medical therapies that have been shown to have
ntifibrotic properties (e.g., inhibitors of the rennin-
ngiotensin/aldosterone system).
Thus, as the list of conditions associated with fibrosis that
an be imaged by CMR grows, the imaging community
ust look toward ways of fine-tuning the imaging to
elineate microscopic fibrosis. Once that is finalized, turn-
ng the identification of fibrosis into therapeutic advances is
n essential next step.
eprint requests and correspondence: Dr. Christopher M.
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